Symptomatic improvement typically begins 2–4 weeks post-infusion and progresses over 8–12 weeks. Functional gains plateau by 5–6 months. Follow-up studies extending to 12–24 months show sustained benefit in approximately 60% of initial responders; others experience gradual symptom recurrence. Some patients require repeat treatment cycles; optimal re-dosing intervals remain unclear.
Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection. Proposed mechanisms include persistent viral fragments in reservoir tissues, endothelial activation with microclot formation, dysregulated immune memory (skewed Th1/Th17 responses, reduced regulatory T cells), and mitochondrial dysfunction. Placental mesenchymal stem cells and exosomes address these pathways through endothelial repair, anti-inflammatory cytokine secretion, and metabolic rescue of dysfunctional immune cells. Eleven registered clinical trials and two actively recruiting protocols evaluate MSC and exosome infusions in long-COVID cohorts, predominantly focusing on severe functional impairment or cardiopulmonary involvement.
האם אני מועמד? → · Long COVID: full overview → · עלות Long COVID → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם